2025³âµµ ¼îÆ®ÄÚ½º

 

Monday, 10 November, 2025

SC1: Best Practices and Advanced Applications for Label-Free Interaction Analysis in Therapeutic Antibody Discovery

Yasmina Abdiche, PhD, Senior Vice President, Exploratory Research, OmniAb Inc.

SC2: Best Practices for Targeting GCPRs, Ion Channels, and Transporters with Monoclonal Antibodies

Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular, Inc.

SC3: Developability of Bispecific Antibodies

Nimish Gera, PhD, Vice President, Biologics, Mythic Therapeutics

SC4: In silico and Machine Learning Tools for Antibody Design and Developability Predictions

Rahmad Akbar, PhD, Senior Data Scientist, Antibody Design, Novo Nordisk
Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.
Odysseas Vavourakis, Generative Antibody Design, University of Oxford

SC5: Novel Payloads and Conjugation Strategies - Building on Lessons Learned to Inform Next-Generation ADC Design

Lenka Sadilkova, PhD, Head, Preclinical R&D, Mablink

* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English_


Catalog Download
Catalog